Side-by-side · Research reference

OvagenvsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BHuman-MechanisticAUTO-DRAFTED11/40 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

Ovagen

Selank

Primary target

Ovarian tissue chromatin complexes

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

Selank

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

150–300 mcg / dose intranasalZaderej 2014

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

2–3× per day during stress

Evidence basis

Theoretical / Russian-tradition

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

10–14 day cycles, repeated as needed

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

—

Lower / starter dose

—

75 mcg / dose

Reconstitution

—

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

—

Morning + early afternoon preferred

Half-life

—

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

Ovagen

Selank

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

—

Long-term safety

Unknown — no PubMed-indexed RCTs

Limited Western RCT data

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

Ovagen

Selank

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Caveat

—

Avoid co-administration with strong sedatives or other anxiolytics initially.